Arcus Biosciences, Inc.
RCUS
$8.62
$0.111.29%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -112.00M | -94.00M | -92.00M | -93.00M | -4.00M |
| Total Depreciation and Amortization | 3.00M | 3.00M | 2.00M | 2.00M | 3.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.00M | 14.00M | 15.00M | 16.00M | 36.00M |
| Change in Net Operating Assets | -37.00M | -23.00M | 101.00M | -19.00M | -37.00M |
| Cash from Operations | -132.00M | -100.00M | 26.00M | -94.00M | -2.00M |
| Capital Expenditure | -1.00M | -1.00M | -1.00M | 0.00 | -4.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.00M | 52.00M | -28.00M | 63.00M | -165.00M |
| Cash from Investing | 32.00M | 51.00M | -29.00M | 63.00M | -169.00M |
| Total Debt Issued | -- | 0.00 | 47.00M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 142.00M | 3.00M | 2.00M | 3.00M | 229.00M |
| Repurchase of Common Stock | -- | -5.00M | -1.00M | -1.00M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 142.00M | -2.00M | 48.00M | 2.00M | 229.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.00M | -51.00M | 45.00M | -29.00M | 58.00M |